Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/chronic-lymphocytic-leukaemia-what-is-new-and-notable-in-2021-with-a-loIlnfKtEG
References (24)
-
K. Fischer, J. Bahlo, A. Fink, V. Goede, C. Herling, P. Cramer, P. Langerbeins, J. Tresckow, A. Engelke, C. Maurer, G. Kovacs, M. Herling, E. Tausch, K. Kreuzer, B. Eichhorst, S. Böttcher, J. Seymour, P. Ghia, P. Marlton, M. Kneba, C. Wendtner, H. Döhner, S. Stilgenbauer, M. Hallek (2016)
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.Blood, 127 2
-
J. Sharman, M. Egyed, W. Jurczak, A. Skarbnik, J. Pagel, I. Flinn, M. Kamdar, Talha Munir, R. Walewska, G. Corbett, L. Fogliatto, Y. Herishanu, V. Banerji, S. Coutre, G. Follows, P. Walker, K. Karlsson, P. Ghia, A. Janssens, F. Cymbalista, J. Woyach, G. Salles, W. Wierda, R. Izumi, V. Munugalavadla, P. Patel, M. Wang, S. Wong, J. Byrd (2020)
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trialThe Lancet, 395
-
J. Seymour, T. Kipps, B. Eichhorst, P. Hillmen, J. D’Rozario, S. Assouline, C. Owen, J. Gerecitano, T. Robak, J. Serna, U. Jaeger, G. Cartron, M. Montillo, R. Humerickhouse, E. Punnoose, Yan Li, M. Boyer, K. Humphrey, M. Mobasher, A. Kater (2018)
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 378
-
S. Treon, J. Castillo, A. Skarbnik, J. Soumerai, I. Ghobrial, M. Guerrera, K. Meid, Guang Yang (2020)
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patientsBlood, 135
-
https (2021)
//www.hematology.org/covid-19/covid-19-and-cll. Accessed 25 July 2021. -
Onko - pedia - Leitlinie Chronische Lymphatische Leukämie ( CLL ) . Stand September 2020 . 2020 -
L. Roeker, D. Knorr, M. Pessin, L. Ramanathan, Meghan Thompson, L. Leslie, A. Zelenetz, A. Mato (2020)
Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemiaLeukemia, 34
-
(2020)
5-year analysis of Murano study demonstrates enduring uMRD in a subset of R/R CLL patients following fixed-duration VenR -
J. Allan, T. Shanafelt, A. Wiestner, C. Moreno, S. O'brien, E. Braggio, Emily Liu, J. Dean, D. Lai, I. Ahn (2020)
Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical TrialsBlood, 136
-
P. Ghia, A. Pluta, M. Wach, D. Lysák, T. Kozák, M. Šimkovič, P. Kaplan, Iryna Kraychok, Á. Illés, J. Serna, S. Dolan, P. Campbell, G. Musuraca, A. Jacob, E. Avery, Jae Lee, Wei Liang, P. Patel, C. Quah, W. Jurczak (2020)
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
-
(2021)
The broadening landscape of targets and therapeuticoptionsforCLL -
B. Eichhorst, A. Fink, J. Bahlo, R. Busch, G. Kovacs, C. Maurer, E. Lange, H. Köppler, M. Kiehl, M. Sökler, R. Schlag, U. Vehling‐Kaiser, G. Köchling, C. Plöger, M. Gregor, T. Plesner, M. Trněný, K. Fischer, H. Döhner, M. Kneba, C. Wendtner, W. Klapper, K. Kreuzer, S. Stilgenbauer, S. Böttcher, M. Hallek (2016)
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.The Lancet. Oncology, 17 7
-
(Wendtner CM, Dreger P, Eichhorst B, et al. Onkopedia-Leitlinie Chronische Lymphatische Leukämie (CLL). Stand September 2020. 2020. http://onkopedia.com/de/onkopedia/guidelines/chronische-lymphatische-leukaemie-cll/@@guideline/html/index.html. Accessed 25 July 2021.)
Wendtner CM, Dreger P, Eichhorst B, et al. Onkopedia-Leitlinie Chronische Lymphatische Leukämie (CLL). Stand September 2020. 2020. http://onkopedia.com/de/onkopedia/guidelines/chronische-lymphatische-leukaemie-cll/@@guideline/html/index.html. Accessed 25 July 2021.Wendtner CM, Dreger P, Eichhorst B, et al. Onkopedia-Leitlinie Chronische Lymphatische Leukämie (CLL). Stand September 2020. 2020. http://onkopedia.com/de/onkopedia/guidelines/chronische-lymphatische-leukaemie-cll/@@guideline/html/index.html. Accessed 25 July 2021., Wendtner CM, Dreger P, Eichhorst B, et al. Onkopedia-Leitlinie Chronische Lymphatische Leukämie (CLL). Stand September 2020. 2020. http://onkopedia.com/de/onkopedia/guidelines/chronische-lymphatische-leukaemie-cll/@@guideline/html/index.html. Accessed 25 July 2021.
-
Clare Sun, C. Pleyer, A. Wiestner (2021)
COVID-19 vaccines for patients with haematological conditionsThe Lancet. Haematology, 8
-
A. Vijenthira, I. Gong, T. Fox, Stephen Booth, G. Cook, B. Fattizzo, F. Martín-Moro, J. Razanamahery, J. Riches, J. Zwicker, R. Patell, M. Vekemans, L. Scarfò, T. Chatzikonstantinou, H. Yildiz, R. Lattenist, I. Mantzaris, W. Wood, L. Hicks (2020)
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patientsBlood, 136
-
J. Woyach, A. Ruppert, N. Heerema, Weiqiang Zhao, Allison Booth, W. Ding, N. Bartlett, D. Brander, P. Barr, K. Rogers, S. Parikh, S. Coutre, A. Hurria, Jennifer Brown, G. Lozanski, J. Blachly, H. Ozer, Brittny Major-Elechi, B. Fruth, S. Nattam, R. Larson, H. Erba, M. Litzow, C. Owen, C. Kuzma, J. Abramson, R. Little, Scott Smith, R. Stone, S. Mandrekar, J. Byrd (2018)
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLLThe New England Journal of Medicine, 379
-
T. Shanafelt, X. Wang, N. Kay, C. Hanson, S. O'brien, J. Barrientos, D. Jelinek, E. Braggio, J. Leis, C. Zhang, S. Coutre, P. Barr, A. Cashen, A. Mato, Avina Singh, M. Mullane, R. Little, H. Erba, R. Stone, M. Litzow, M. Tallman (2019)
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.The New England journal of medicine, 381 5
-
Y. Herishanu, I. Avivi, A. Aharon, G. Shefer, S. Levi, Yotam Bronstein, M. Morales, T. Ziv, Yamit Arbel, L. Scarfò, E. Joffe, C. Perry, P. Ghia (2021)
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemiaBlood, 137
-
A. Chanan-Khan, P. Cramer, F. Demirkan, G. Fraser, Rodrigo Silva, S. Grosicki, A. Pristupa, A. Janssens, J. Mayer, N. Bartlett, M. Dilhuydy, H. Pylypenko, J. Loscertales, A. Avigdor, S. Rule, D. Villa, O. Samoilova, P. Panagiotidis, A. Goy, A. Mato, M. Pavlovsky, C. Karlsson, M. Mahler, M. Salman, Steven Sun, C. Phelps, S. Balasubramanian, A. Howes, M. Hallek (2016)
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.The Lancet. Oncology, 17 2
-
Dreger P Wendtner CM (2020)
//onkopedia.com/de/onkopedia/guidelines/chronische-lymphatische-leukaemie-cll/@@guideline/html/index.html. Accessed 25 July 2021. -
A. Kater, T. Kipps, B. Eichhorst, P. Hillmen, J. D’Rozario, C. Owen, S. Assouline, N. Lamanna, Tadeusz Robak, J. Serna, U. Jaeger, G. Cartron, M. Montillo, C. Mellink, B. Chyla, C. Wilson, J. Wu, Yanwen Jiang, M. Lefebure, M. Boyer, J. Seymour (2020)
Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)Blood, 136
-
V. Goede, K. Fischer, R. Busch, A. Engelke, B. Eichhorst, C. Wendtner, T. Chagorova, J. Serna, M. Dilhuydy, T. Illmer, Stephen Opat, C. Owen, O. Samoylova, K. Kreuzer, S. Stilgenbauer, H. Döhner, A. Langerak, M. Ritgen, M. Kneba, E. Asikanius, K. Humphrey, M. Wenger, M. Hallek (2014)
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.The New England journal of medicine, 370 12
-
Talha Munir, Jennifer Brown, S. O'brien, J. Barrientos, P. Barr, N. Reddy, S. Coutre, C. Tam, S. Mulligan, U. Jaeger, T. Kipps, C. Moreno, M. Montillo, J. Burger, J. Byrd, P. Hillmen, S. Dai, A. Szoke, J. Dean, J. Woyach (2019)
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphomaAmerican Journal of Hematology, 94
-
K. Fischer, O. Al-Sawaf, J. Bahlo, A. Fink, M. Tandon, M. Dixon, S. Robrecht, S. Warburton, K. Humphrey, O. Samoylova, A. Liberati, J. Pinilla-Ibarz, Stephen Opat, L. Sivcheva, K. Dû, L. Fogliatto, C. Niemann, R. Weinkove, S. Robinson, T. Kipps, S. Boettcher, E. Tausch, R. Humerickhouse, B. Eichhorst, C. Wendtner, A. Langerak, K. Kreuzer, M. Ritgen, V. Goede, S. Stilgenbauer, M. Mobasher, M. Hallek (2019)
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.The New England journal of medicine, 380 23
- Publisher
- Springer Journals
- Copyright
- 2021 Springer-Verlag GmbH Austria, part of Springer Nature
- ISSN
- 1865-5041
- eISSN
- 1865-5076
- DOI
- 10.1007/s12254-021-00735-z
- Publisher site
- See Article on Publisher Site
Abstract
Summary In the last few years, treatment of patients exhibiting chronic lymphocytic leukaemia has changed extensively due to advances in the development of targeted therapies. The role of immunochemotherapy has been for the most part replace and the guidelines have been modified accordingly. Herein, we give an overview on updated onkopedia guidelines, studded with updates of the landmark studies of the latest American Society of Hematology (ASH) meeting. In addition, since still crucial, recommendations concerning coronavirus disease 2019 (COVID-19) in chronic lymphocytic leukaemia patients will be covered.
Journal
memo - Magazine of European Medical Oncology – Springer Journals
Published: Sep 1, 2021
Keywords: oncology; medicine/public health, general